Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
Open Access
- 6 September 2010
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 478
- https://doi.org/10.1186/1471-2407-10-478
Abstract
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons. Using this treatment regimen, overall survival could be extended significantly however, median overall survival is still only about 15 months.Keywords
This publication has 26 references indexed in Scilit:
- Carbon ion radiation therapy for high-risk meningiomasRadiotherapy and Oncology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Carbon ion radiotherapy for pediatric patients and young adults treated for tumors of the skull baseCancer, 2009
- Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell linesInternational Journal of Radiation Biology, 2009
- Particle Radiation Therapy Using Proton and Heavier Ion BeamsJournal of Clinical Oncology, 2007
- Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized TrialJournal of Clinical Oncology, 2006
- Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single InstitutionJournal of Clinical Oncology, 2005
- Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniquesCancer, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Survival and Failure Patterns of High-Grade Gliomas After Three-Dimensional Conformal RadiotherapyJournal of Clinical Oncology, 2002